After listening to Webcast of Mithra
2019 Annual Report. It was interesting
to hear firstly comments regarding
Mayne Pharma and then during Question
by Analysts one queried why Mayne
paid such a Premium compared to other
Distributors????
The answer I found somewhat baffling.
Mithra somehow seemed to claim R and D
other scenarios ! I would appreciate an
Accountant to listen to same and give me
a better understanding. Since Mayne did deal
this has long been an huge cost to me.
I calculated $500m plus for E4 at time.
Still Extraordinary to me.
New Product Approvals, page-205
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.57 |
Change
0.120(2.70%) |
Mkt cap ! $388.7M | |||
| Open | High | Low | Value | Volume |
| $4.46 | $4.68 | $4.44 | $1.261M | 274.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8445 | $4.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.61 | 135 | 1 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| MYX (ASX) Chart |